Tesofensine and semaglutide target fundamentally different neurobiological mechanisms: tesofensine inhibits monoamine reuptake to suppress appetite centrally, while semaglutide activates GLP-1 receptors to regulate glucose and satiety
Diabetes Obes Metab 20(5):12021212
Additionally, the nausea and mild gastrointestinal adjustments common with tirzepatide can contribute to dehydration and head discomfort
The other interesting thing to note about the Eli Lilly license, David, which I thought was really clever, is it's a one year exclusive license where there are two conditions, and the conditions are a trade
have declared that no competing interests exist
Temporary protecting groups help prevent unwanted reactions, while deprotection steps expose the next reactive site for coupling